Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $40.78, for a total transaction of $815,600.00. Following the transaction, the executive vice president owned 60,000 shares of the company’s stock, valued at approximately $2,446,800. This represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Marshall Urist also recently made the following trade(s):

• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $39.32, for a total value of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total value of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total value of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total value of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Stock Performance

Shares of RPRX traded up $0.10 during midday trading on Tuesday, reaching $40.36. The stock had a trading volume of 4,907,357 shares, compared to its average volume of 3,801,906. The firm has a market cap of $23.30 billion, a PE ratio of 30.58, a P/E/G ratio of 1.93 and a beta of 0.43. The firm has a 50 day simple moving average of $39.24 and a 200-day simple moving average of $37.33. Royalty Pharma PLC has a one year low of $29.66 and a one year high of $41.70. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The business had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. As a group, sell-side analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be paid a dividend of $0.235 per share. The ex-dividend date is Friday, February 20th. This represents a $0.94 annualized dividend and a dividend yield of 2.3%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio is presently 66.67%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on RPRX shares. The Goldman Sachs Group started coverage on Royalty Pharma in a report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target for the company. Weiss Ratings lowered shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Leerink Partners set a $45.00 target price on shares of Royalty Pharma in a research note on Thursday, December 11th. Morgan Stanley decreased their price target on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Finally, Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Royalty Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.60.

Institutional Investors Weigh In On Royalty Pharma

A number of large investors have recently bought and sold shares of the company. Nordea Investment Management AB lifted its holdings in shares of Royalty Pharma by 603.9% during the 2nd quarter. Nordea Investment Management AB now owns 655,995 shares of the biopharmaceutical company’s stock worth $23,701,000 after acquiring an additional 562,799 shares during the period. Watchtower Advisors LP bought a new position in Royalty Pharma in the second quarter valued at approximately $3,603,000. World Investment Advisors acquired a new position in Royalty Pharma during the third quarter valued at approximately $1,702,000. Financiere des Professionnels Fonds d investissement inc. acquired a new position in Royalty Pharma during the third quarter valued at approximately $933,000. Finally, Generali Asset Management SPA SGR lifted its stake in Royalty Pharma by 7,752.8% during the third quarter. Generali Asset Management SPA SGR now owns 34,081 shares of the biopharmaceutical company’s stock worth $1,202,000 after purchasing an additional 33,647 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.